It is well documented that chemical carcinogenesis results in tumours that are resistant to the cytotoxic and growth inhibitory effects of various carcinogens [Carr, 1987] . Interestingly, there exists a remarkable parallel between the biochemical changes with carcinogen resistance and multidrug-resistance. The most frequently reported alteration in multidrug resistant cells, namely the overexpression of the 170 kDa membrane glycoprotein, is also found in both preneoplastic and neoplastic lesions producd by carcinogens [Thorgeirsson et al., 1987; Fairchild et al., 1987; Gottesman, 1988; Volm et al., 1990] . Since human lung carcinoma is predominantly caused by cigarette smoking [Doll & Peto, 1981] test were clinically progressive (98%) and 40 of 58 tumours that tested sensitive showed clinical remission (69%). There was also good agreement between the in vitro test results and survival. Similar results were obtained in subsequent studies [Volm et al., 1985a [Volm et al., ,b, 1988 . These results have recently been confirmed by Khoo et al. (1989) and Auner et al. (1989) .
As expected, the lung tumours in the present study responded very differently in the in vitro test system. Forty-one (25%) out of 160 tumours were classified as sensitive and 119 tumours (75%) as resistant. In Table II the relationship between test results in vitro (sensitive/resistant) and smoking (nonsmokers/smokers) of all analysed non-small cell lung carcinomas are presented. A significant relationship between smoking and response of the tumours to doxorubicin in vitro was found (P = 0.002). Carcinomas of smokers tended to be resistant more frequently (81 %) than carcinomas of nonsmokers (53%). Similar results were obtained when the analysis was restricted only to those patients with epidermoid lung carcinomas (P = 0.001). Of the tumours of smokers 91 %, and of the tumours of non-smokers 50% were resistant. In contrast to these data there exists no relationship between resistance and smoking for adenocarciomas of the lung. This may be expected because adenocarcinomas are said to be less frequently associated with smoking than are epidermoid lung carcinomas [Gould & Warren, 1989] . We further analysed the patients with regard to the number of cigarettes smoked and to cessation of smoking and could not find any influence of these factors (data not shown). Until now, the mechanisms for the resistance of lung tumours are unknown and may be multifactorial. It can be speculated that, as a detoxifying transport system, the P-glycoprotein might be increased with other known detoxifying systems such as glutathione transferase, cytochrome P-450 isoforms and topoisomerase II. Whereas Lai et al. (1989) demonstrated only a weak expression of the multidrug-resistance (MDR) gene in 14 out of 24 human lung tumours, Radosevich et al. (1989) found P-glycoprotein expressing cells in 100 out of 131 non-small cell lung carcinomas by immunohistochemical techniques. We recently investigated the intrinsic resistance of a panel of human epidermoid lung cancer xenografts grown in nude mice [Volm et al., 1989b] and found a correlation between expression of P-glycoprotein and degree of resistance. Carmichael et al.
(1988) measured glutathione levels in 30 human lung cancer lines and found lower levels in cell lines derived from small cell lung cancer specimens compared to non-small cell lung cancer. Non-small cell lung cancers were found to have increased activity of 4 detoxification enzymes (glutathione transferase, glutathione reductase, y-glutamyl transpeptidase, superoxide dismutase) compared to small cell lung tumours. These differences in glutathione levels and detoxification enzyme levels may also prove to be important causes for intrinsic drug resistance often seen in patients with non-small cell lung cancer. Zijlstra et al. (1987) demonstrated that the resistance in a doxorubicin-resistant human lung carcinoma cell line was multifactorial with decreased intracellular doxorubicin levels, increased DNA repair, and altered doxorubicin-topoisomerase interaction. Investigations are continuing in our laboratory to determine which mechanisms of resistance of lung tumours are active.
